Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion
NCT03025360
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Tumors Harboring NTRK Fusion
Interventions
DRUG:
Larotrectinib (Vitrakvi, BAY2757556)
Sponsor
Bayer